Morgan Stanley raised the firm’s price target on BeOne Medicines (ONC) to $330 from $313 and keeps an Overweight rating on the shares following the R&D day that highlighted the company’s pipeline programs. Management is targeting a 2026 approval for Sonrotoclax and 2027 approval for BGB16673, notes the analyst, who contends that Street estimates for BGB-16673 and Sonrotoclax are “too conservative.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines price target raised to $321 from $317 at JPMorgan
- BeiGene’s Robust Oncology Pipeline and Strategic Developments Justify Buy Rating with $300 Price Target
- Beigene’s Promising Phase 1 Study on BGB-21447 for Metastatic Breast Cancer
- BeiGene’s Zanubrutinib Study: A Potential Game-Changer for B-Cell Lymphoma Treatment
- Beigene’s Zanubrutinib Study: A Potential Game-Changer in Nephropathy Treatment?